# Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

Study · id `cardio:ct-nct04388215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04388215](<https://clinicaltrials.gov/study/NCT04388215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04388215

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04388215. Randomized; quadruple masking; primary purpose treatment. Start 2019-10-23 (actual); primary completion 2021-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04388215, source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)
- Started: 2019-10-23 (actual) (ClinicalTrials.gov record NCT04388215, source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)
- Primary completion: 2021-04 (anticipated) (ClinicalTrials.gov record NCT04388215, source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)
- Completion: 2021-04 (anticipated) (ClinicalTrials.gov record NCT04388215, source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04388215, source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04388215-2020-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet
- Condition: Hypertension
- Condition: Dyslipidemias
- Intervention (Drug): CKD-828
- Intervention (Drug): CKD-828(placebo)
- Intervention (Drug): D326
- Intervention (Drug): D326(placebo)
- Intervention (Drug): D337
- Intervention (Drug): D337(placebo)
- Intervention (Drug): D013
- Intervention (Drug): D013(placebo)
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: bf10fc26bb97191526db6b2a0992aa6a1d910e1d3ff6a36e16f02c495bcb7912
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
